TRESIBA
Drug
Novo Nordisk AS
Total Payments
$192,982
Transactions
87
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $192,982 | 87 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $192,982 | 87 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN1250-4419 | Novo Nordisk AS | $148,764 | 0 |
| NN1250-4252 | Novo Nordisk AS | $36,543 | 0 |
| NN9535-4270 | Novo Nordisk AS | $7,675 | 0 |
Top Doctors Receiving Payments for TRESIBA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Toledo, OH | $192,982 | 87 |
Ad
Manufacturing Companies
- Novo Nordisk AS $192,982
Product Information
- Type Drug
- Total Payments $192,982
- Total Doctors 0
- Transactions 87
About TRESIBA
TRESIBA is a drug associated with $192,982 in payments to 0 healthcare providers, recorded across 87 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2019 to 2019. In 2019, $192,982 was paid across 87 transactions to 0 doctors.
The most common payment nature for TRESIBA is "Unspecified" ($192,982, 100.0% of total).
TRESIBA is associated with 3 research studies, including "NN1250-4419" ($148,764).